Although biomarker-based classification is advancing, particularly in AD due to the availability of amyloid and tau positron emission tomography imaging, clinical diagnosis remains central for diseases such as PD and FTD, where such imaging tools are lacking. This evidence concerns the gene MAPT and Parkinson disease.